⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asparagine SCHEMBL2927424 | 0.88 | SLC1A3 (0.32) | — | |
| Asparagine SCHEMBL7855644 | 0.83 | SLC1A3 (0.34) | — | |
| Asparagine SCHEMBL2902050 | 0.74 | SLC1A3 (0.34) | — | |
| Asparagine SCHEMBL2902137 | 0.67 | MC4R (0.35) | — | |
| Asparagine SCHEMBL2902032 | 0.66 | — | — | |
| Asparagine SCHEMBL7855451 | 0.61 | MC4R (0.36) | — | |
| Asparagine SCHEMBL28219869 | 0.57 | SLC7A5 (0.52) | — | |
| Asparagine SCHEMBL8892693 | 0.56 | SLC7A5 (0.58) | — | |
| Asparagine SCHEMBL8892690 | 0.56 | SLC7A5 (0.58) | — | |
| Dl-Phenylalanine SCHEMBL28019412 | 0.55 | SLC7A5 (0.69) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239270-A2 | Low molecular weight peptide derivatives as inhibitors of the Laminin/Nidogen interaction | Sanofi-Aventis Deutschland GmbH (DE) | 2010-10-13 | — | — | EP | disclosed |
| EP-1845106-B1 | Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-08-11 | — | — | EP | disclosed |
| EP-1845106-A1 | Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction | Sanofi-Aventis Deutschland GmbH (DE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1157040-B1 | LOW MOLECULAR WEIGHT PEPTIDE DERIVATIVES AS INHIBITORS OF THE LAMININ/NIDOGEN INTERACTION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-6365572-B1 | FOR THERAPY OF DISEASES RELATED TO INCREASED OR UNWANTED SYNTHESIS OF BASEMENT MEMBRANES SUCH AS DIABETES MELLITUS; ATHEROSCLEROSIS; CANCER; DIABETIC RETINOPATHIA; FIBROPLASIA RETROLENTALIS; OR PSORIASIS, RHEUMATOIC ARTHRITIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-02 | — | — | US | disclosed |
| EP-1157040-A1 | LOW MOLECULAR WEIGHT PEPTIDE DERIVATIVES AS INHIBITORS OF THE LAMININ/NIDOGEN INTERACTION | Aventis Pharma Deutschland GmbH (DE) | 2001-11-28 | — | — | EP | disclosed |
| EP-1070727-A1 | Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction | Aventis Pharma Deutschland GmbH (DE) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000052051-A1 | LOW MOLECULAR WEIGHT PEPTIDE DERIVATIVES AS INHIBITORS OF THE LAMININ/NIDOGEN INTERACTION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-09-08 | — | — | WO | disclosed |